Product Description
Mitoxantrone injection is used alone or together with other medicines to treat advanced prostate cancer and acute nonlymphocytic leukemia (ANLL). It belongs to the group of medicines known as antineoplastics or cancer medicines. Mitoxantrone is also used to treat some forms of multiple sclerosis (MS). This medicine will not cure MS, but it may extend the time between relapses. (Sourced from: https://www.mayoclinic.org/drugs-supplements/mitoxantrone-intravenous-route/description/drg-20064849)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CSPC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Spain, United States
Active Clinical Trial Count: 33
Highest Development Phases
Phase 3: Gastrointestinal Cancer|Nasopharyngeal Cancer|T-Cell Peripheral Lymphoma
Phase 2: Acute Myeloid Leukemia|Biphenotypic Acute Leukemia|Breast Cancer|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders|Neuromyelitis Optica|Pancreatic Cancer|Preleukemia|Transitional Cell Carcinoma
Phase 1: Acute Monocytic Leukemia|Head and Neck Cancer|Hepatocellular Carcinoma|Lymphoma|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified|Ovarian Cancer|Sarcoma|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CSPC-DED-AML-K15 | P2 |
Recruiting |
Acute Myeloid Leukemia |
2027-12-31 |
|
| HE071-CSP-013 | P3 |
Not yet recruiting |
T-Cell Peripheral Lymphoma |
2027-12-30 |
52% |
| HE071-CSP-013 | P3 |
Not yet recruiting |
T-Cell Peripheral Lymphoma |
2027-12-30 |
52% |
| FXMH-AML-002 | P2 |
Recruiting |
Acute Myeloid Leukemia |
2026-12-31 |
|
| 24-0178.cc | P1 |
Recruiting |
Acute Monocytic Leukemia|Acute Myeloid Leukemia |
2026-12-01 |